Similar Posts
US stock: Key news, insider trading, valuation & analysts
Trump’s letter to Norway pretty much sums it up: “Considering your Country decided not to give me the Nobel Peace Prize for having stopped 8 Wars PLUS, I no longer feel an obligation to think purely of Peace…” The US President sent that out along with several ultimatums demanding the US annex Greenland. Europe is…
Markets overview. US Labour market readings key for the dollar this week – ForexNews.PRO
USDThe dollar underperformed our expectations throughout last month, with the DXY index sinking almost 3.5% by August 27th. That said, a rally into month-end gives us confidence that markets are starting to come to their senses. As we have noted previously, the dollar now looks distinctly cheap at current levels. US growth remains strong, and…
Options Trading Strategies
How the Day-Trading Options Market Works Options Trading Strategies While watching a business news segment, you may have heard that over 100 million stock options traded in a single day. This number is staggeringbut accurate. Research shows that average daily stock options volume ranges from 50–60 million contracts, with high-volatility days pushing volume…
CAB Payments to Cut 20% of Workforce
CAB Payments Holdings announced plans to reduce its workforce by approximately 20% as part of a strategic cost improvement exercise. The company announced the move in its 2024 pre-close trading update on Thursday, explaining that it is aimed at aligning the company’s operational structure with its growth ambitions and improving operational leverage. The decision comes…
Cboe Launches New Timestamping Service
Cboe Global Markets revealed Monday that it has introduced a new Timestamping Service that provides market participants with extra order and cancel-related timestamp information. The company explained that the service enhances market transparency and efficiency, offering traders insights into order execution and cancellation processes. They added that the new service is available on all Cboe-affiliated…
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) has released promising results from the Phase 3 QUASAR trial, assessing the effectiveness of EYLEA HD (aflibercept) Injection 8 mg for addressing macular edema linked to retinal vein occlusion (RVO). This encompasses patients with central, branch, and hemiretinal vein occlusions. The findings from this trial will inform a supplemental Biologics License…
